In addition, the frequent loss of G1 checkpoint control in HR-NB, by MYCN amplification and p53 pathway loss at relapse, provide a rationale for treatment with G2 checkpoint targeting agents (ATR, CHK1, and/or WEE1 inhibitors). This evidence concerns the gene WEE1 and neuroblastoma.